NEW YORK (GenomeWeb News) – Luminex today reported a 51 percent increase in fourth-quarter revenues and a sharp uptick in profits, due to a settlement payment received during the quarter.
 
The results include the combined operations of Luminex and Tm Bioscience, which Luminex acquired for $44 million last March and renamed Luminex Molecular Diagnostics.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.